Galectin Therapeutics (GALT) Gains from Sales and Divestitures (2010 - 2025)

Galectin Therapeutics (GALT) recorded quarterly Gains from Sales and Divestitures of $334000.0 in Q4 2025, up 902.01% quarter-over-quarter from $33333.0 in Q4 2012.

Galectin Therapeutics (GALT) Gains from Sales and Divestitures (2010 - 2025) Analysis & Trends

Galectin Therapeutics' Gains from Sales and Divestitures history runs 4 years deep, the most recent figure standing at $334000.0 for Q4 2025.

  • In Q4 2025, Gains from Sales and Divestitures changed N/A year-over-year to $334000.0; the TTM figure through Dec 2025 stood at $334000.0 (changed N/A YoY), while the FY2025 annual figure was $334000.0, changed N/A from the prior year.
  • Gains from Sales and Divestitures was $334000.0 for Q4 2025 at Galectin Therapeutics, up from $33333.0 in the prior quarter.
  • In the past five years, Gains from Sales and Divestitures ranged from a high of $334000.0 in Q4 2025 to a low of $334000.0 in Q4 2025.
Generated on {Timestamp} © BusinessQuant.com
Generated on {Timestamp} Powered by BusinessQuant Logo

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Alterity Therapeutics 925,601.88 Bn 925,601.85 Bn -
2 Belite Bio 58,560.00 Bn 58,560.00 Bn -
3 Quantum Biopharma 17,284.41 Bn 17,284.40 Bn -
4 Legend Biotech 2,809.00 Bn 2,808.71 Bn 242.10 Mn
5 Evaxion A 1,334.43 Bn 1,334.42 Bn -
6 Akari Therapeutics 1,312.27 Bn 1,312.26 Bn -
7 Psyence Biomedical 212.16 Bn 212.16 Bn -
8 Vertex Pharmaceuticals 114.83 Bn 107.58 Bn 2.59 Bn
9 Abivax 91.96 Bn 91.96 Bn -
10 Galectin Therapeutics 185.83 Mn 171.73 Mn -

Historic Data

Download Data
DateValue
Dec 31, 2025 334,000.00
Dec 31, 2025 334,000.00
Dec 31, 2012 33,333.00
Dec 31, 2012 33,333.00
Dec 31, 2011 390,628.00
Dec 31, 2011 390,628.00
Jun 30, 2011 45,000.00
Jun 30, 2011 45,000.00
Dec 31, 2010 74,000.00
Dec 31, 2010 74,000.00
Jun 30, 2010 25,000.00
Jun 30, 2010 25,000.00